Improved Intratumoral Oxygenation Through Vascular Normalization Increases Glioma Sensitivity to Ionizing Radiation

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 5, 2010, Pages 1537-1545

  McGee, Mackenzie C ^a   Hamner, J Blair ^a,b   Williams, Regan F ^a,b   Rosati, Shannon F ^a   Sims, Thomas L ^a,b   Ng, Catherine Y ^a   Gaber, M Waleed ^b   Calabrese, Christopher ^a   Wu, Jianrong ^a   Nathwani, Amit C ^c   Duntsch, Christopher ^b   Merchant, Thomas E ^a   Davidoff, Andrew M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

bevacizumab; glioma; interferon ; ionizing radiation; oxygenation; Vascular normalization

Indexed keywords

ANTI-TUMOR ACTIVITIES; BEVACIZUMAB; BIOLUMINESCENCE IMAGING; CELLULAR PHENOTYPES; CRANIAL IRRADIATION; CYTOTOXIC ACTIVITIES; GLIOMA; IMMUNOHISTOCHEMICAL STAINING; MONO-THERAPY; ORTHOTOPIC; RADIORESISTANCE; TUMOR GROWTH; TUMOR OXYGENATION; TUMOR VASCULATURE; VASCULAR NORMALIZATION;

ANTIBIOTICS; ENDOTHELIAL CELLS; GLYCOPROTEINS; IONIZING RADIATION; OXYGENATION; RADIATION SHIELDING; RADIOACTIVITY; TUMORS;

OXYGENATORS;

BEVACIZUMAB; RECOMBINANT BETA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; GLIOMA; HYPOXYPROBE STAINING; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; MALE; MONOTHERAPY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; OXYGENATION; PHENOTYPE; PRIORITY JOURNAL; RADIOSENSITIVITY; SINGLE DRUG DOSE; SKULL IRRADIATION; STAINING; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL HYPOXIA; GLIOMA; INTERFERON-BETA; MALE; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN CONSUMPTION; RADIATION TOLERANCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 77949553030     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.12.010     Document Type: Article

References (39)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 10 (2005) 987-996
2. Wrensch M., Minn Y., Chew T., et al. Epidemiology of primary brain tumors: Current concepts and review of the literature. Neurooncol 4 (2002) 278-299
3. Fischer I., Gagner J., Newcomb E., et al. Angiogenesis in gliomas: Biology and molecular pathophysiology. Brain Pathol 15 (2005) 297-310
4. Brown J., and Giaccia A. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58 (1998) 2408-2416
5. Plate K.H., Breier G., Weich H.A., et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359 (1992) 845-848
6. Plate K.H., Breier G., Millauer B., et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53 (1993) 5822-5827
7. Salmaggi A., Eoli M., Frigerio S., et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 62 (2003) 297-303
8. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
9. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
10. Kaur B., Tan C., Bratt D., et al. Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 70 (2004) 229-243
11. Cairns R., Papandreou I., and Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4 (2006) 61-70
12. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
13. Fidler I.J., and Ellis L.M. Neoplastic angiogenesis-Not all blood vessels are created equal. N Engl J Med 351 (2004) 215-216
14. Martinive P., De Wever J., Bouzin C., et al. Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol Cancer Ther 5 (2006) 1620-1627
15. Tannock I.F. Tumor physiology and drug resistance. Cancer Metastasis Rev 20 (2001) 123-132
16. Mottram J. Factors of importance in radiosensitivity of tumors. Br J Radiol 9 (1926) 606
17. Overgaard J., and Horsman M. Modification of hypoxia induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6 (1996) 10-21
18. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25 (2007) 4066-4074
19. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29 (1994) 427-431
20. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7 (2001) 987-989
21. Le Serve A.W., and Hellman K. Metastases and the normalization of tumour blood vessels by ICRF 159: A new type of drug action. BMJ 1 (1972) 597-601
22. Teicher B.A., Holden S.A., Ara G., et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 57 (1994) 920-925
23. Dings R.P., Williams B.W., Song C.W., et al. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 62 (2002) 1702-1706
24. Dings R.P., Loren M., Heun H., et al. Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13 (2007) 3395-3402
25. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-562
26. Dickson P., Hamner J., Streck C., et al. Continuous delivery of interferon beta promotes sustained maturation of intratumoral vasculature. Mol Cancer Res 5 (2007) 531-542
27. Gerber H.P., and Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65 (2005) 671-680
28. Dickson P.V., Hamner J.B., Sims T.L., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13 (2007) 3942-3950
29. Hurwtiz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
30. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
31. Streck C., Dickson P., Ng C., et al. Adeno-associated virus vector-mediated systemic delivery of interferon-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models. Clin Cancer Res 11 (2005) 6020-6029
32. Benjamin R., Kwaja A., Singh N., et al. Continuous delivery of human type I interferons (alpha/beta) has significant activity against acute myeloid leukemia cells in vitro and in a xenografts model. Blood 109 (2007) 1244-1247
33. Davidoff A.M., Ng C.Y., Sleep S., et al. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J Virol Methods 121 (2004) 209-215
34. Streck C., Dickson P., Ng C., et al. Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta. Cancer Gene Ther 13 (2006) 99-106
35. Szentirmai O., Baker C., Lin N., et al. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 58 (2006) 365-372
36. Dickson P.V., Ng C.Y., Zhou J., et al. In vivo bioluminescence imaging for early detection and monitoring of disease progression in murine model of neuroblastoma. J Pediatr Surg 42 (2007) 1172-1179
37. Plackett R.L., and Hewlett P.S. Statistical aspects of the independent joint action of poisons, particularly insecticides: The toxicity of a mixture of poisons. Ann Appl Biol 35 (1948) 347-358
38. Dickson P., Hagedorn N., Hamner J., et al. Interferon beta-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model. J Pediatr Surg 42 (2007) 160-165
39. Schmidberger H., Rave-Frank M., Lehmann J., et al. Lack of interferon-beta induced radiosensitization in four out of five human glioblastoma cell lines. Int J Radiat Oncol Biol Phys 55 (2003) 1348-1357